Related Experiment Video
Updated: May 24, 2026
08:56
Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
Published on: November 30, 2022
[Diclofenac induced liver injuries]
L Nezic1, S Krähenbühl, A E Rätz Bravo
1Abteilung für Klinische Pharmakologie und Toxikologie und Regionales Pharmacovigilance-Zentrum Basel.
Praxis
|March 16, 2012
Summary
An 83-year-old female experienced diclofenac-induced liver injury after nine days of treatment for back pain. Symptoms resolved upon discontinuation, highlighting NSAID-related liver damage risks.
Area of Science:
- Pharmacology
- Hepatology
- Clinical Medicine
Background:
- Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), is frequently prescribed for pain management.
- NSAID-induced liver injury (DILI) is a recognized, albeit uncommon, adverse drug reaction.
- Understanding DILI is crucial for patient safety and effective pain management strategies.
Observation:
- An 83-year-old female developed liver injury nine days after initiating diclofenac therapy for chronic lumbovertebral pain.
- The patient's symptoms and liver function normalized after discontinuing diclofenac.
- This case underscores the potential for diclofenac to cause hepatotoxicity.
Findings:
- Diclofenac-associated liver injury can manifest acutely following therapeutic initiation.
- The adverse reaction profile of diclofenac includes potential hepatotoxicity.
- NSAID-induced liver injury exhibits varied clinical presentations and underlying mechanisms.
Implications:
- Clinicians should maintain a high index of suspicion for DILI in patients presenting with liver abnormalities during NSAID therapy.
- Awareness of risk factors and preventive measures is essential for mitigating NSAID-related liver injury.
- Further research into NSAID hepatotoxicity mechanisms can inform safer prescribing practices.
Related Concept Videos
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:24Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
01:17Gastritis-II: Pathophysiology
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...